Keyword: Christophe Weber
Worries about competition to Shire's bread-and-butter hemophilia franchise were clear even before Takeda bought it. That fear has become reality.
The majority of investors backed a proposal that would allow Takeda to claw back executive pay should the Shire deal not live up to expectations.
Takeda, in its first year counting the Shire business, managed to turn up revenue growth. But the upcoming fiscal year could be a different story.
Takeda will probably not sell its OTC business to help pay off the $31 billion loan it’s taking to finance the Shire takeover, its CEO says.
The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.
With a critical shareholder vote looming, Takeda's CFO says the company will consider selling up to $10 billion in assets to help fund its Shire buy.
Takeda CEO Christophe Weber and Nissan's now-fallen chairman Carlos Ghosn have much more in common than their French nationality.
Ahead of an early December shareholder vote on Takeda's Shire buyout, some Takeda investors and insiders are working to gather support against it.
Takeda is eager to close its Shire deal and take the specialty pharma under its wing, but for now it's highlighting a few strengths in its own business.
Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.